Management of Non-metastatic Castration Resistant Prostate Cancer (nmCRPC): Putting current evidence into practice

Patients with non-metastatic castration-resistant prostate cancer (nmCRPC) have rising prostate-specific antigen (PSA) and castrate testosterone levels, with no radiological findings of metastatic disease on computed tomography and bone scan.

Published Wed, 2 Mar 2022
E CourseProstate CancerOncology
Organiser European School of Urology (ESU)
Duration Approx. 50 minutes

Given recent drug approvals for nmCRPC, with many other therapeutics and imaging modalities being developed, management of nmCRPC is a rapidly evolving field that merits detailed investigation. The aims of this UROwebinar are to review current nmCRPC management practices and identify opportunities for improving care of nmCRPC patients.

Topic: Prostate cancer

CME: An application for this webinar has been submitted
Duration: Approx. 45 – 60 minutes

Contact our organiser

European School of Urology (ESU)